Trial
NCT03082300
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Non-small Cell Lung Cancer (NSCLC)
Intervention
naquotinib
Why stopped
Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-20